08.07.2014 • News

BioAmber Secures $7 Million Grant for Canadian Plant

The Canadian subsidiary of US biotechnology pioneer BioAmber has nailed down a $7 million grant to support the ongoing construction of a $135 million bio-succinic acid plant currently under construction in Sarnia, Ontario.

The grant from Sustainable Development Technology Canada (SDTC) is on top of a $7.5 million grant SDTC provided to BioAmber Sarnia in 2012.

When the Canadian plant using corn-derived feedstock goes on stream in early 2015, BioAmber said it expects it to be the world's largest succinic acid production facility.

"BioAmber secured this additional funding after expanding the scope of the Sarnia plant, nearly doubling the production capacity from 17,000 t/y to 30,000 t/y," the company said in a statement.

"The SDTC grant also supports the switch to BioAmber's second-generation yeast, which proved to be significantly more cost competitive than the bacteria-based fermentation originally designed to operate in Sarnia," it added.

"Commercializing an innovative, clean technology that is cost disruptive to the petrochemical industry is a major undertaking, and it needs government support to become a reality," Mike Hartmann, BioAmber's executive vice president, said."

From Lab to Market Challenge

Vote Now: Germany's Most Promising Chemistry Start-ups
Choose your favourite among the finalists

Vote Now: Germany's Most Promising Chemistry Start-ups

The "From Lab to Market Challenge" brings together the most promising founders from chemistry, materials science, and industrial biotechnology. Starting June 1st, you can cast your public vote for the finalists on CHEManager.com — before the award ceremony with €10,000 in prizes takes place on June 25th.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read